Viridian Therapeutics Inc. Common Stock (VRDN)

About VRDN

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-st…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

252

Website

www.viridiantherapeutics.com/

Fundamentals

1-day range

$22.57$23.61

Market cap

$2.32B

P/E (trailing)

—

P/E (forward)

-8.51

EPS (trailing)

$-3.90

Dividend yield

—

Beta

1.09

Avg. volume

2.07M

Dividend pay date

November 13, 2020

Forecasts

16 analyst ratings

Viridian Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• VRDN

  Viridian Therapeutics Inc. Common Stock

  $23.09

  ▼ 3.31%
  Market cap $2.32BP/E —
  $13.18$34.29
• VERA

  Vera Therapeutics Inc. Class A Common Stock

  $34.19

  ▼ 1.18%
  Market cap $2.30BP/E —
  $21.2$56.05
• MLYS

  Mineralys Therapeutics Inc. Common Stock

  $25.59

  ▼ 1.61%
  Market cap $2.23BP/E —
  $14.94$47.65
• URGN

  UroGen Pharma Ltd. Ordinary Shares

  $43.61

  ▼ 4.15%
  Market cap $2.22BP/E —
  $15.86$50.81
• KLRA

  Kailera Therapeutics Inc. Common Stock

  $16.26

  ▼ 12.25%
  Market cap $2.44BP/E —
  $16.19$28.23
• SLS

  SELLAS Life Sciences Group Inc. Common Stock

  $13.17

  ▼ 13.45%
  Market cap $2.18BP/E —
  $1.39$15.88
• BHVN

  Biohaven Ltd. Common Shares

  $15.42

  ▼ 4.37%
  Market cap $2.17BP/E —
  $7.48$18.57

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36
  benzinga · 8/7/2026
• RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36
  Benzinga · 8/7/2026
• Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39
  Benzinga · 8/7/2026
• Viridian Therapeutics Q2 EPS $(1.05) Misses $(1.02) Estimate, Sales $233.000K Beat $22.308K Estimate
  Benzinga · 8/6/2026
• Amgen: First $10 Billion Quarter, More Growth Ahead
  SeekingAlpha · 8/5/2026

• CAIN CHRISTOPHER W. · July 1, 2026 · Grant

  32.3K
• Moses Jennifer K. · July 1, 2026 · Grant

  32.3K
• Gheuens Sarah · July 1, 2026 · Grant

  32.3K
• Kiselak Tomas · July 1, 2026 · Grant

  32.3K
• Ajer Jeffrey Robert · July 1, 2026 · Grant

  32.3K
• Arlene Morris · July 1, 2026 · Grant

  32.3K
• Fairmount Healthcare Fund II L.P. · May 11, 2026 · Buy

  1.18M @ $17
• Harmon Seth · March 3, 2026 · Tax Withholding

  2.0K @ $30.19
• Beetham Thomas W. · March 3, 2026 · Tax Withholding

  3.0K @ $30.19
• Tousignant Jennifer · March 3, 2026 · Tax Withholding

  1.7K @ $30.19
• Mahoney Stephen F. · March 3, 2026 · Tax Withholding

  7.4K @ $30.19
• Tousignant Jennifer · March 3, 2026 · Option Exercise

  5.2K
• Tousignant Jennifer · March 3, 2026 · Tax Withholding

  1.7K @ $29.32
• Harmon Seth · March 3, 2026 · Option Exercise

  6.3K
• Harmon Seth · March 3, 2026 · Tax Withholding

  2.1K @ $29.32

Institutional Ownership

March 31, 2026

Total shares held

109.40M

Total value held

$2.08B

Institutional holders

218